p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice

Esther Landesman-Bollag, Padma L. Channavajhala, Robert Cardiff, David C. Seldin

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation. Here we demonstrate that CK2α transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene. Lymphomas originating from CK2α transgenic mice that are heterozygous for p53 generally lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2α transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.

Original languageEnglish (US)
Pages (from-to)2965-2974
Number of pages10
JournalOncogene
Volume16
Issue number23
DOIs
StatePublished - Jun 11 1998

Fingerprint

Casein Kinase II
Lymphoma
Transgenic Mice
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Protein-Serine-Threonine Kinases
Cell Cycle Checkpoints
Transgenes
Neoplasms
Cell Cycle
Leukemia
Transcription Factors
Alleles
Phosphorylation
Apoptosis
Messenger RNA
Mutation

Keywords

  • Casein kinase II
  • Lymphoma
  • Oncogene
  • p53
  • Protein kinase
  • Transgenic mice

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. / Landesman-Bollag, Esther; Channavajhala, Padma L.; Cardiff, Robert; Seldin, David C.

In: Oncogene, Vol. 16, No. 23, 11.06.1998, p. 2965-2974.

Research output: Contribution to journalArticle

Landesman-Bollag, Esther ; Channavajhala, Padma L. ; Cardiff, Robert ; Seldin, David C. / p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. In: Oncogene. 1998 ; Vol. 16, No. 23. pp. 2965-2974.
@article{d5c6716f78c04c22a11a862de20adf05,
title = "p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice",
abstract = "Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation. Here we demonstrate that CK2α transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene. Lymphomas originating from CK2α transgenic mice that are heterozygous for p53 generally lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2α transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.",
keywords = "Casein kinase II, Lymphoma, Oncogene, p53, Protein kinase, Transgenic mice",
author = "Esther Landesman-Bollag and Channavajhala, {Padma L.} and Robert Cardiff and Seldin, {David C.}",
year = "1998",
month = "6",
day = "11",
doi = "10.1038/sj.onc.1201854",
language = "English (US)",
volume = "16",
pages = "2965--2974",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "23",

}

TY - JOUR

T1 - p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice

AU - Landesman-Bollag, Esther

AU - Channavajhala, Padma L.

AU - Cardiff, Robert

AU - Seldin, David C.

PY - 1998/6/11

Y1 - 1998/6/11

N2 - Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation. Here we demonstrate that CK2α transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene. Lymphomas originating from CK2α transgenic mice that are heterozygous for p53 generally lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2α transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.

AB - Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation. Here we demonstrate that CK2α transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene. Lymphomas originating from CK2α transgenic mice that are heterozygous for p53 generally lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2α transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.

KW - Casein kinase II

KW - Lymphoma

KW - Oncogene

KW - p53

KW - Protein kinase

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0032507966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032507966&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1201854

DO - 10.1038/sj.onc.1201854

M3 - Article

C2 - 9662328

AN - SCOPUS:0032507966

VL - 16

SP - 2965

EP - 2974

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 23

ER -